Content area
Full Text
Frost & Sullivan (Palo Alto, CA), a market growth consulting and research firm, released analysis on February 25 indicating that the North American nuclear medicine equipment market may recover more quickly than expected from the effects of the Deficit Reduction Act (DRA) of 2005. Driving this positive news are the SPECT and SPECT/CT segments of the market, which, according to the analysis, are opening up "numerous lucrative opportunities in niche markets such as neuroendocrine tumor imaging." The North American SPECT and SPECT/ CT markets earned revenues of $298-4 million in 2007 and are estimated to reach $325.3 million in 2014.
In a related press release. Frost & Sullivan Research Analyst Travis...